Atara Biotherapeutics, Inc. (ATRA)

0,6998 -0,0149 (-2,08%) Al cierre: 04:00PM EDT

Atara Biotherapeutics, Inc.

2380 Conejo Spectrum Street
Suite 200
Thousand Oaks, CA 91320
United States
805 623 4211
https://www.atarabio.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 225

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Pascal Touchon D.V.M.	President, CEO & Director	1,08M	N/A	1963
Mr. K. Amar Murugan	Executive VP & Chief Legal Officer	618,52k	N/A	1976
Mr. Eric Hyllengren	Executive VP & Chief Financial Officer	N/A	N/A	1976
Dr. Anhco Nguyen Ph.D.	Executive VP and Chief Scientific & Technical Officer	N/A	N/A	1973
Alex Chapman	Vice President of Corporate Communications & Investor Relations	N/A	N/A	N/A
Ms. Jill Henrich	Executive VP and Global Head of Regulatory Affairs & Quality	N/A	N/A	1963
Mr. Dan Maziasz	Executive VP & Chief Business Officer	N/A	N/A	N/A
Ms. Rajani Dinavahi M.D.	Senior VP & Chief Medical Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Gobierno corporativo

El ISS Governance QualityScore de Atara Biotherapeutics, Inc., a día 1 de abril de 2024, es 6. Las puntuaciones base son Auditoría: 6; Tablero: 5; Derechos de los accionistas: 8; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.